LIPIXELLE^TM  Technology is a platform for solubilizing ophthalmic drugs with limited water solubility or completely insoluble ophthalmic drugs The currently marketed Latanoprost Eye Drops contain Benzalkonium Chloride (BAK). BAK is a common preservative in topical ocular preparations; however, prolonged use may lead to deleterious effects on the ocular surface, affecting quality of life and reducing adherence to treatment and overall outcomes.

SPARC has developed LIPIXELLE^TM Technology platform to formulate Latanoprost in to a novel clear, colorless, BAK-free Ophthalmic Emulsion.

This technology does not require the use of quaternary ammonium preservative/surfactant like Benzalkonium Chloride which may be damaging to the eye.

Key Features & Benefits

• BAK-Free platform for solubilizing ophthalmic drugs with limited water solubility or completely insoluble ophthalmic drugs
• Uses nonionic surfactant (NIS) to solubilize Latanoprost
• Contains known ocular lubricant which fortifies the lipid layer in formation of tear film, and uncharged coating is soft to eye surface
• Reduces risk of ocular surface damage on chronic use
• Prevents drug from environmental temperature and light fluctuations; stable at room temperature; does not require refrigeration upon storage / transport